Haruto Kurata

This inventor holds 8 USPTO granted patents and 3 published patent applications and 6 EPO patents. Top assignees: Ono Pharmaceutical Co., Ltd., Vanderbilt University. Active years: 2009-2023.

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 25.0

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 31(Granted Patents)

Location History:

Mishima-gun, JP (2009 - 2014)
Osaka, JP (2013 - 2023)

Company Filing History:

8 out of 575

Ono Pharmaceutical Co., Ltd.

patents

2 out of 1,218

Vanderbilt University

patents

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11851428 - Activator of TREK (TWIK RElated Kchannels) channels (2023-12-26),

2. 11471436 - Dihydronaphthalene derivative (2022-10-18),

3. 11046683 - Activator of TREK (TWIK RElated Kchannels) channels (2021-06-29),

4. 8791159 - Compound capable of binding S1P receptor and pharmaceutical use thereof (2014-07-29),

5. 8575134 - Aminocarboxylic acid derivative and medicinal use thereof (2013-11-05),

6. 7906549 - Aminocarboxylic acid derivative and medicinal use thereof (2011-03-15),

7. 7825109 - Compound capable of binding S1P receptor and pharmaceutical use thereof (2010-11-02),

8. 7511159 - Azetidine ring compounds and drugs comprising the same (2009-03-31),

Title: Haruto Kurata: Innovator in Neurodegenerative Disease Treatment

Introduction

Haruto Kurata is a prominent inventor based in Mishima-gun, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target specific receptors related to neurodegenerative diseases. With a total of eight patents to his name, Kurata's work is paving the way for new therapeutic options.

Latest Patents

One of Kurata's latest patents is focused on an activator of TREK (TWIK Related Kchannels) channels. This patent discloses a compound represented by a specific formula, which has selective S1P5 receptor agonist activity. The compound, a dihydronaphthalene derivative, is designed to treat S1P5-mediated diseases, including neurodegenerative conditions such as schizophrenia. The innovative design of this compound includes a short linker from a phenyl group to a cyclic substituent, enhancing its therapeutic potential.

Career Highlights

Throughout his career, Haruto Kurata has worked with notable organizations, including Ono Pharmaceutical Co., Ltd. and Vanderbilt University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Kurata has collaborated with esteemed colleagues such as Shinji Nakade and Hiromu Habashita. These partnerships have been instrumental in advancing his research and patent developments.

Conclusion

Haruto Kurata's innovative work in the field of neurodegenerative disease treatment exemplifies the impact of dedicated inventors in the pharmaceutical industry. His contributions continue to inspire advancements in medical science.